23. H. D. Nelson et al., "Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA– Related Cancer in Women: A Systematic Review to Update the US Preventive Services Task Force Recommendation," Annals of Internal Medicine 160 (2014): 255–266.

24. G. Rennert et al., "Clinical Outcomes of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations," New England Journal of Medicine 357, no. 2 (2007): 115–123.

25. R. Winslow, "Early Ovary Removal Reduces Long-Term Cancer Risk: Study," Wall Street Journal, February 24, 2013, http://online.wsj.com/news/article_email/ SB10001424052702304834704579403421175065210 -lMyQ jAxMTA0MDIwNTEyNDUyWj.

26. A. P. Finch et al., "Impact of Oophorectomy on Cancer Incidence and Mortality in Women with a BRCA1 or BRCA2 Mutation," Journal of Clinical Oncology 32, no. 15 (2014): 1549–1554.

27. N. D. Kauff et al., "Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation," New England Journal of Medicine 346, no. 21 (2002): 1609–1615.

28. S. J. Hoffman and C. Tan, "Following Celebrities' Medical Advice: Meta-Narrative Analysis," British Medical Journal 347 (2013): f 7151.

29. J. Bulluz and S. J. Hoffman, "Katie Couric and the Celebrity Medicine Syndrome," Los Angeles Times, December 18, 2013, http://www.latimes.com/opinion/commentary/la-oe-hoffman-celebrities-health-advice-20131218,0,3861833.story.

30. K. Kamenova, A. Reshef, and T. Caulfield, "Angelina Jolie's Faulty Gene: Newspaper Coverage of a Celebrity's Preventive Bilateral Mastectomy in Canada, the United States, and the United Kingdom," Genetics in Medicine 16, no. 7 (2013): 522–528, http://www.nature.com/gim/journal/ vaop/ncurrent/full/gim2013199a.html.

31. "Myriad Genetics Q1 Revenues Shoot up 52 Percent; Angelina Jolie Effect Cited," GenomeWeb, November 6, 2013, http://www.genomeweb.com/clinical-genomics/myriad-genetics-q1-revenues-shoot-52-percent-angelina-jolie-effect-cited.

32. R. C. Rabin, "In Israel, a Push to Screen for Cancer Gene Leaves Many Conflicted," New York Times, November 27, 2013, http://www.nytimes.com/2013/11/27/health/in-israel-a-push-to-screen-for-cancer-gene-leaves-many-conflicted.html.

33. E. Murphy, "Inside 23andMe Founder Anne Wojcicki's $99 DNA Revolution," Fast Company, October 14, 2013: http://www.fastcompany.com/3018598/for-99-this-ceo-can-tell-you-what-might-kill-you-inside-23andme-founder-anne-wojcickis-dna-r.

34. FDA, "Inspections, Compliance, Enforcement, and Criminal Investigations: Warning Letter to Ann Wojcicki," November 22, 2013, http://www.fda.gov/ICECI/EnforcementActions/ WarningLetters/2013/ucm376296.htm.

35. A. Pollack, "FDA Orders Genetic Testing Firm to Stop Selling DNA Analysis Service," New York Times, November 26, 2013, http://www.nytimes.com/2013/11/26/business/fda-demands-a-halt-to-a-dna-test-kits-marketing.html.

36. A. Pollack, "Genetic Tester to Stop Providing Data on Health Risks," New York Times, December 6, 2013, http://www.nytimes.com/2013/12/06/business/genetic-tester-to-stop-providing-data-on-health-risks.html.

37. F. Polli, "Why 23andMe Deserves a Second Chance," Forbes, January 14, 2014, http://www.forbes.com/sites/fridapolli/2014/01/14/why-23andme-deserves-a-second-chance/.

38. T. Ray, "Facing FDA Warning Letter and Lawsuit, Can 23andMe Stay True to Its DTC Credo in 15 Days?" GenomeWeb, December 4, 2013, http://www.genomeweb.com/print/1319176?utm_source=SilverpopMai%C9 PGx Uncertainty.

39. R. Rekhi, "A Government Ban on 23andMe's Genetic Testing Services Ignores Reality," The Guardian, December 4, 2013, http://www.theguardian.com/commentisfree/2013/dec/04/23andme-consumer-genomics-fda-ban-regulation/print.

40. R. Khan, "The FDA's Battle With 23andMe Won't Mean Anything in the Long Run," Slate, November 25, 2013, http://www.slate.com/blogs/future_tense/2013/11/25/fda _letter_to_23andme_won_t_mean_anything_in_the_long_run.html.

41. R. Khan and D. Mittelman, "Rumors of the Death of Consumer Genomics Are Greatly Exaggerated," Genome Biology 14 (2013): 139, http://genomebiology.com/2013/14/11/139.

42. C. J. Janssens, "It Is Game Over for 23andMe, and Rightly So," The Conversation, November 26, 2013, http://theconversation.com/it-is-game-over-for-23andme-and-rightly-so-20744.

43. L. Jamal, "What Do We Gain or Lose by Regulating 23andMe?" Berman Institute of Bioethics Bulletin, November 27, 2013, http://bioethicsbulletin.org/archive/what-do-we-gain-or-lose-by-regulating-23andme/print/.

44. T. Hay, "23andMe Flap With FDA Just a Bump in the Road, One Genetics-Testing Investor Says," Wall Street Journal, December 16, 2013, http://blogs.wsj.com/venturecapital/2013/12/16/23andme-flap-with-fda-just-a-bump-in-the-road-one-genetics-testing-investor-says/tab/print/.

45. H. Greely, "The FDA Drops an Anvil on 23andMe – Now What?" Law and Biosciences Blog, November 25, 2013, https://blogs.law.stanford.edu/lawandbiosciences/2013/11/25/the-fda-drops-an-anvil-on-23andme-now-what/.

46. M. F. Murray, "Why We Should Care About What We Get for 'Only $99' From a Personal Genomic Service," Annals of Internal Medicine 160, no. 7 (2014): 507–508.

47. G. Neff, "In the Battle Over Personal Health Data, 23andMe and the FDA Are Both Wrong," Slate, December 13, 2013, http://www.slate.com/blogs/future_tense/2013/ 12/13/_23andme_vs_the_fda_both_are_wrong.html.

48. R. Bailey, "Let My Genes Go! And Leave 23andMe Alone," Reason.com, November 29, 2013, http://reason.com/archives/2013/11/29/why-the-fda-should-leave-23andme-alone/print.

49. S. Usdin, "The Sky Isn't Falling," BioCentury, June 17, 2013, http://www.biocentury.com/biotech-pharma-news/politics/2013-06-17/scotus-myriad-protects-biotech-patenting-but-leaves-important-gray-areas-a13.

50. E. Vayena, "Direct-to-Consumer Genomics on the Scales of Autonomy," Journal of Medical Ethics, May 5, 2014, http://jme.bmj.com/content/early/2014/05/05/medethics-2014-102026.full.

51. J. K. Wagner, "The Sky Is Falling for Personal Genomics! Oh, Nevermind. It's Just a Cease & Desist Letter from the FDA to 23andMe," Genomics Law Report, December 3, 2013, http://www.genomicslawreport.com/index.php/2013/12/03/the-sky-is-falling-for-personal-genomics-oh-nevermind-its-just-a-cease-desist-letter-from-the-fda-to-23andme/.

52. "Doing the Genomic Revolution Right," Huffngton Post, December 20, 2013, http://www.huffingtonpost.com/tricia-page/doing-the-genomic-revolution-right_b_4480887.html?view=print&comm_ref=false.

53. A. J. Burke, "23andMe's FDA Battle Provokes Furious Debate," Techonomy, December 2, 2013, http://techonomy.com/2013/12/just-tip-iceberg-23andme-medicine/.